Biotronik reports positive trial data for Pantera Lux

Biotronik has reported positive clinical registry data that underlines the safety and efficacy benefits provided by its Pantera Lux paclitaxel-releasing balloon.

Six-month data from the Delux registry – which consisted predominantly of in-stent restenotic patients – demonstrated very low rates of major adverse cardiac events and revascularisation, among both diabetic and non-diabetic patients.

It suggests that the device could provide a viable alternative treatment option for patients with in-stent restenosis or diabetes, conditions which are often complex to treat.

Biotronik's Pantera Lux utilises a highly deliverable Pantera semi-compliant balloon coated with a matrix of proven antiproliferative paclitaxel and the biocompatible butyryl-tri-hexyl citrate excipient, thus enabling optimal drug transfer to the target lesion tissue.

Alain Aimonetti, vice-president of sales and marketing at Biotronik's vascular intervention division, said: "The excellent results across different indications strengthen our firm belief that the Pantera Lux can be a valuable tool outside of in-stent restenosis and allow us to continue our exploration into other therapy areas."

This week, the company also announced positive data from a study of Passeo-18 Lux , its peripheral vascular paclitaxel-releasing balloon.